Abstract
Malignant melanoma is a relatively rare but potentially aggressive tumor in children and adolescents. We report the case of a metastatic malignant melanoma in a 17-year-old girl, first diagnosed on cytological features of a fine-needle lymph node aspiration and then histologically confirmed by both examination of the metastatic adenopathy and a clinically harmless skin lesion of the scalp, which harbored focal microscopic pattern of melanoma. A fluorescent in situ hybridization study revealed that both metastatic and primary cutaneous tumours contained the same and pejorative chromosomal aberration consisting in CCND1 amplification (11q13). This observation raises actual limits and challenges in the fields of diagnosis and treatment of fast-killing melanomas.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Adolescent
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Back Pain / etiology
-
Combined Modality Therapy
-
Cyclin D1 / genetics
-
Dacarbazine / therapeutic use
-
Drug Resistance, Neoplasm
-
Fatal Outcome
-
Female
-
Gene Amplification
-
Head and Neck Neoplasms / diagnosis*
-
Head and Neck Neoplasms / drug therapy
-
Head and Neck Neoplasms / genetics
-
Head and Neck Neoplasms / pathology
-
Head and Neck Neoplasms / surgery
-
Humans
-
Immunotherapy
-
In Situ Hybridization, Fluorescence
-
Ipilimumab
-
Lymphatic Metastasis / diagnosis
-
Melanoma / diagnosis*
-
Melanoma / drug therapy
-
Melanoma / genetics
-
Melanoma / pathology
-
Melanoma / secondary
-
Melanoma / surgery
-
Nausea / etiology
-
Neoplasm Proteins / genetics
-
Neoplasms, Second Primary / diagnosis*
-
Neoplasms, Second Primary / genetics
-
Neoplasms, Second Primary / pathology
-
Nevus / pathology
-
Osteolysis / etiology
-
Scalp / pathology*
-
Skin Neoplasms / diagnosis*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / pathology
-
Weight Loss
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Alkylating
-
CCND1 protein, human
-
Ipilimumab
-
Neoplasm Proteins
-
Cyclin D1
-
Dacarbazine